asa glp-1 agonists Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 GLP-1 medications safe to continue

45 Remarkably, the recent SELECT trial proved the cardiovascular efficacy of subcutaneous semaglutide in reducing the primary cardiovascular composite endpoint (death from cardiovascular causes, non-fatal MI or non-fatal stroke) in both overweight and obese patients with established atherosclerotic CVD

For context on the broader legal status of peptides in sports and research contexts, that guide provides a useful framework

However, this perspective overlooks the broader impact of these medications on optimizing surgical outcomes, reducing complications, and expanding access to surgery for higher-risk patients

Wegovy and Saxenda are the only GLP-1 supplements approved as weight loss drugs